Ocular Therapeutix (OCUL) Set to Announce Earnings on Tuesday

Ocular Therapeutix (NASDAQ:OCUL) is expected to be releasing its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect Ocular Therapeutix to announce earnings of ($0.3635) per share and revenue of $14.27 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:00 AM ET.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.05. Ocular Therapeutix had a negative return on equity of 59.89% and a negative net margin of 579.10%. The firm had revenue of $13.47 million for the quarter, compared to analysts’ expectations of $13.20 million. During the same period in the prior year, the business earned ($0.39) EPS. The company’s revenue for the quarter was down .1% compared to the same quarter last year. On average, analysts expect Ocular Therapeutix to post ($1.47) EPS for the current fiscal year and ($1.35) EPS for the next fiscal year.

Ocular Therapeutix Price Performance

Shares of NASDAQ OCUL opened at $6.47 on Tuesday. The firm’s 50-day moving average price is $9.14 and its 200-day moving average price is $9.21. Ocular Therapeutix has a 1-year low of $6.00 and a 1-year high of $16.44. The firm has a market capitalization of $1.42 billion, a P/E ratio of -4.56 and a beta of 1.00. The company has a current ratio of 13.10, a quick ratio of 13.03 and a debt-to-equity ratio of 0.14.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Royal Bank Of Canada reiterated an “outperform” rating on shares of Ocular Therapeutix in a report on Tuesday, September 29th. Zacks Research upgraded Ocular Therapeutix from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ocular Therapeutix in a research note on Thursday, October 15th. UBS Group began coverage on Ocular Therapeutix in a research note on Sunday, October 11th. They issued a “buy” rating and a $14.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating on shares of Ocular Therapeutix in a research note on Tuesday, October 20th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $22.86.

Insider Transactions at Ocular Therapeutix

In other Ocular Therapeutix news, insider Todd Anderman sold 11,984 shares of the company’s stock in a transaction that occurred on Thursday, October 8th. The shares were sold at an average price of $7.29, for a total value of $87,363.36. Following the completion of the transaction, the insider directly owned 140,484 shares in the company, valued at $1,024,128.36. This represents a 7.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Jeffrey Heier sold 10,869 shares of the stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $7.05, for a total value of $76,626.45. Following the completion of the sale, the insider owned 307,457 shares of the company’s stock, valued at $2,167,571.85. The trade was a 3.41% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 62,720 shares of company stock worth $556,247. 3.10% of the stock is owned by company insiders.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc (NASDAQ:OCUL) is a biopharmaceutical company focused on developing and commercializing therapies for diseases and conditions affecting the eye. The company uses its proprietary hydrogel-based drug-delivery technology to provide sustained or controlled release of medicines in ophthalmic applications.

Its commercial products include Dextenza, a dexamethasone ophthalmic insert used to treat ocular inflammation and itching following ophthalmic surgery, and Yutiq, a fluocinolone acetonide intravitreal implant indicated for the treatment of chronic noninfectious posterior uveitis.